Galmed Pharmaceuticals Reports $19.2M Cash Position, Advancing Clinical Development

Written by Emily J. Thompson, Senior Investment Analyst

GLMD.O-0.88%

Source: PRnewswire

Updated: 5 day ago

0mins

Source: PRnewswire

Strong Cash Position: Galmed Pharmaceuticals ended Q3 2025 with approximately $19.2 million in cash and virtually no debt, ensuring operational flexibility while increasing R&D investments to support expanded clinical studies, thereby providing a solid foundation for executing both short and long-term development plans.
Significant Clinical Advancements: The recent Phase 3 results for Aramchol in MASH and liver fibrosis showed that 65% and 100% of patients experienced fibrosis improvement at week 48, indicating substantial commercial potential in a market projected to reach $16 billion by 2033 due to high unmet needs.
New Drug Combination Development: Galmed is developing a new sublingual formulation of Aramchol for combination therapy with other metabolic agents, which, if successful, will allow for the prompt initiation of a Phase 2 clinical study in MASH, significantly expanding its market opportunities in liver disease.
Oncology Expansion: Early findings from combination studies of Aramchol with Stivarga indicate enhanced efficacy against various GI cancers, with plans to initiate clinical trials for metastatic colorectal cancer and hepatocellular carcinoma in early 2026, further solidifying the company's strategic positioning in oncology.

GLMD.O

$0.0000%Past 6 months

Line

Candle

YTD

No Data

Intellectia

Analyst Views on GLMD

About GLMD

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.